公开(公告)号：WO2013012199A8

公开(公告)日：2014-02-06

申请号：PCT/KR2012005506

申请日：2012-07-11

Applicant: HANMI PHARM IND CO LTD ,  KIM YONG IL ,  KIM DONG HO ,  KWON TAEK KWAN ,  KIM KYEONG SOO ,  PARK JAE HYUN ,  WOO JONG SOO

Inventor： KIM YONG IL ,  KIM DONG HO ,  KWON TAEK KWAN ,  KIM KYEONG SOO ,  PARK JAE HYUN ,  WOO JONG SOO

IPC: A61K9/48 ,  A61K31/47 ,  A61K31/4704 ,  C07D215/18

CPC classification number: A61K9/4808 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/4816 ,  A61K31/47 ,  A61K31/473 ,  A61K31/495 ,  A61K31/4965 ,  C07D215/12 ,  C07D295/06 ,  C07D295/08 ,  A61K2300/00

Abstract: Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.

Abstract translation: 公开了一种用于预防或治疗过敏性鼻炎和哮喘的胶囊制剂，其包含两个单独的层：（1）包含孟鲁司特或其药学上可接受的盐的蒙特卡斯特层; 和（2）包含左西替利嗪或其药学上可接受的盐的左西替利嗪层; 及其制备方法。 根据本发明的胶囊制剂可以完全分离两种活性成分，从而最小化它们之间的反应性并提高产品对抗老化作用的稳定性，从而可以优化治疗效果。

公开(公告)号：WO2013012199A1

公开(公告)日：2013-01-24

申请号：PCT/KR2012/005506

申请日：2012-07-11

Applicant: HANMI PHARM. CO., LTD. ,  KIM, Yong Il ,  KIM, Dong Ho ,  KWON, Taek Kwan ,  KIM, Kyeong Soo ,  PARK, Jae Hyun ,  WOO, Jong Soo

Inventor： KIM, Yong Il ,  KIM, Dong Ho ,  KWON, Taek Kwan ,  KIM, Kyeong Soo ,  PARK, Jae Hyun ,  WOO, Jong Soo

IPC: A61K9/48 ,  A61K31/47 ,  A61K31/4704 ,  C07D215/18

CPC classification number: A61K9/4808 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/4816 ,  A61K31/47 ,  A61K31/473 ,  A61K31/495 ,  A61K31/4965 ,  C07D215/12 ,  C07D295/06 ,  C07D295/08 ,  A61K2300/00

Abstract: Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.

Abstract translation: 公开了一种用于预防或治疗过敏性鼻炎和哮喘的胶囊制剂，其包含两个单独的层：（1）包含孟鲁司特或其药学上可接受的盐的蒙特卡斯特层; 和（2）包含左西替利嗪或其药学上可接受的盐的左西替利嗪层; 及其制备方法。 根据本发明的胶囊制剂可以完全分离两种活性成分，从而最小化它们之间的反应性并提高产品对抗老化作用的稳定性，从而可以优化治疗效果。